Latest hepatitis B Stories
PARIS, October 21, 2011 /PRNewswire/ -- - Hepatitis B is one of the most common infectious diseases in the world, with 350 million people worldwide being chronically infected[1]- this compares with 33 million people living with HIV infection[2]- yet there remains a lack of reliable resources for hepatitis B patientsand caregivers - PATH B - "Patients and Professionals Acting Together for Hepatitis B" (...
ALEXANDRIA, Va., Oct. 20, 2011 /PRNewswire/ -- AASLD President's Press Conference Saturday, November 5, 2011 - 4:00-5:00 pm Room 2011, Moscone West Convention Center San Francisco, California AASLD President T. Jake Liang, MD, will host a press conference on the first full day of presentations at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases. Dr. Liang will highlight individual studies and themes from the 2300 abstracts to be...
AMARILLO, Texas, Oct. 14, 2011 /PRNewswire/ -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today provided an update on company activities. Oral Interferon Phase 2 Hepatitis C Study Nearing Completion ABI's oral interferon research continues. Results from a Phase 2, dose-ranging study of oral interferon for the prevention of relapse in hepatitis C patients are expected in the first quarter of 2012. A Phase 2 study of oral IFN, in combination with Tamiflu, for the treatment of influenza...
SYDNEY, Oct. 10, 2011 /PRNewswire-Asia/ -- Phase 2a trial validates Biotron's novel drugFirst-in-class new, oral drugGood results on tolerability and efficacyFull data to be presented to scientific conference in DecemberAustralian drug development company Biotron Limited (ASX:BIT) has released headline results from its landmark Phase 2a trial of its lead drug candidate, BIT225 in Hepatitis C virus (HCV) infected patients. Preliminary analysis of trial data confirms that BIT225, an orally...
BLUE BELL, Pa., Oct. 10, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc. (KSE:011000), to co-develop Inovio's SynCon® therapeutic vaccines for hepatitis B and C infections. Under the terms of the agreement, VGX International will receive marketing...
HOERSHOLM, Denmark, and SAN DIEGO, Oct. 3, 2011 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA and mRNA-targeted therapies, today announced the Company will report new clinical data results from the miravirsen Phase 2a proof-of-concept study to treat patients infected with the Hepatitis C virus (HCV) in a late-breaking oral presentation session at the American Association for the Study of Liver Diseases...
Making prescription drugs affordable EDMONTON, Sept. 28, 2011 /PRNewswire/ - Compass Biotechnologies, Inc. (COBI: OB) prepares to market, sell and distribute recombinant human cytokines and growth factors for research purposes. Further to the recent announcement of the expanding Compass's agreement with Pangen Biotech of South Korea, Compass branded cytokine and growth factors research reagents will be the first products to be offered through this growing relationship....
CompassBiotech Making prescription drugs affordable EDMONTON, Sept. 27, 2011 /PRNewswire/ - Compass Biotechnologies (COBI:OB) is a product-oriented specialty biotechnology company focused on offering products for multi-billion dollar markets. The company is pleased to announce it has entered into an expanded relationship with PanGen Biotech of South Korea, which will allow Compass to offer a globally marketed comprehensive laboratory reagents product line for sale under...
CompassBiotech Making Drugs to Combat Major Human Diseases EDMONTON, Sept. 26, 2011 /PRNewswire/ - Compass (COBI:OB) is pleased to announce new research findings that it believes will alter the course of HCV vaccine development and other vaccines in general. Vaccine products continue to be the success story for pharmaceutical companies, with the world market for preventative vaccines in 2010 being $ 28 billion as compared to $26 billion in 2009, $24 billion in 2008 and $18.5...
Scientist suggests that squalamine be explored as a human antiviral agent based on the reported discovery and its known safety profile in humans A compound initially isolated from sharks shows potential as a unique broad-spectrum human antiviral agent, according to a study led by a Georgetown University Medical Center investigator and reported in the Proceedings of the National Academy of Sciences Early Edition online September 19. The compound, squalamine, has been in human clinical...
Latest hepatitis B Reference Libraries
Image Caption: This electron micrograph reveals the presence of hepatitis-B virus HBV "Dane particles", or virions. Credit: CDC/Wikipedia Hepatitis B: What Is It? Hepatitis simply means a swelling or inflammation of the liver. The type hepatitis that a person contracts (there are 5 common forms) affects their long-term prognosis. The most common and most severe of these different types of liver infection is Hepatitis B, which is caused by the hepatitis B virus (HBV). It is typically...
Hepatitis A, caused by hepatitis A virus, is an acute infectious disease of the liver that is transmitted person to person by ingestion of contaminated food or water or through direct contact with an infectious person. Millions of people are believed to become infected with HAV every year. The incubation period is two to six weeks and on average is 28 days. In less developed countries the HAV is usually contracted in early childhood. Clean water helps to decrease contraction of HAV. In 90%...
Hepatitis B virus, HBV, is a part of the Hepadnaviridae family of viruses. HBV can lead to cirrhosis and hepatocellular carcinoma and has been linked to pancreatic cancer. It is classified as a species of the Orthohepadnavirus. Similar viruses have been found worldwide in great apes and monkeys. There a few different genotypes and they all differ by at least 8% of the sequence and have distinct geographical distributions and this has been associated with anthropological history. Type A is...
Hepadnaviruses can cause liver infections in humans and animals. The two recognized genera are Genus Orthohepadnavirus and Genus Avihepadnavirus. It has a small genome of partially double-stranded, partially single stranded circular DNA. It is a group 7 virus that uses an RNA intermediate during replication. Most people who come into contact with the virus are able to clear the infection alone although some cannot and usually progress to fulminant hepatitis. It can cause sever liver...
